Skip to main content
KAZIA THERAPEUTICS LTD logo

KAZIA THERAPEUTICS LTD — Investor Relations & Filings

Ticker · KZIA ISIN · US48669G1058 US Professional, scientific and technical activities
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2025-07-09 Regulatory Filings
Country US United States of America
Listing US KZIA

About KAZIA THERAPEUTICS LTD

https://www.kaziatherapeutics.com/

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company engaged in the development of innovative drugs for cancer. The company's lead program is paxalisib, a small molecule inhibitor of the PI3K/AKT/mTOR pathway designed to cross the blood-brain barrier, which is being investigated for various forms of brain cancer. Its development pipeline also includes EVT801, a selective VEGFR3 inhibitor being studied for its potential to block the growth of blood and lymphatic vessels that support tumor growth. The company focuses on addressing cancers with high unmet medical needs through its portfolio of targeted therapies.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Kazia Therapeutics Limited, with the SEC. It reports the issuance of a press release about early efficacy data from a clinical trial. The document is short (2160 characters) and primarily serves to announce and incorporate by reference a press release (Exhibit 99.1). There is no substantive financial data or detailed report content within this filing itself. According to the 'Menu vs Meal' rule, this is an announcement of a report (press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2025-07-09 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-06-13 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-06-12 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It includes a press release about preclinical data and clinical trial updates, and it references a prospectus supplement related to a registration statement. The document does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is primarily an update and supplement to a prospectus and includes a press release about scientific and clinical developments. The document length is 11,587 characters, which is substantial but the content is focused on a prospectus supplement and a press release rather than a full financial report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories such as Annual Report, Interim Report, or Capital/Financing Update. The presence of a Form 6-K and the nature of the content confirm this classification.
2025-06-11 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It includes a press release announcing preclinical data and clinical trial updates related to their drug paxalisib. The document is a regulatory filing that provides supplemental information to previously filed registration statements and annual reports (Form 20-F). It does not contain comprehensive financial statements or detailed financial analysis typical of annual or interim reports. It also does not fit into categories like earnings release, capital update, or management changes. The document is primarily a regulatory disclosure of new scientific and clinical information, making it best classified as a Regulatory Filing (RNS). The document length (11,588 characters) and content confirm it is not a brief announcement or a full report but a formal regulatory filing with substantive information.
2025-06-11 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer pursuant to SEC rules. It includes a press release about preclinical data and clinical trial updates, and references a prospectus supplement related to a registration statement on Form F-1. The document does not contain comprehensive financial statements or detailed financial analysis typical of annual or interim reports. It is primarily an update and supplement to a prospectus and includes a press release about scientific and clinical developments. The document is about regulatory disclosure of current information and updates rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-06-11 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.